{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:00:41Z","timestamp":1791133241561,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1093\/neuonc\/not226","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T01:59:27Z","timestamp":1386727167000},"page":"392-399","source":"Crossref","is-referenced-by-count":52,"title":["Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma"],"prefix":"10.1093","volume":"16","author":[{"given":"Emeline","family":"Tabouret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Boudouresque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Boucard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Loundou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Metellus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Figarella-Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L'Houcine","family":"Ouafik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,9]]},"reference":[{"key":"key\n\t\t\t\t20170508185152_NOT226C1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CCO.0b013e32833edc0c","article-title":"Bevacizumab: current updates in treatment","volume":"22(6)","author":"Van Meter","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor\u2013induced angiogenesis suppresses tumour growth in vivo","volume":"362(6423)","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170508185152_NOT226C3","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27(28)","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28(4)","author":"Chinot","year":"2011","journal-title":"Adv Ther"},{"key":"key\n\t\t\t\t20170508185152_NOT226C5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2009.24.8021","article-title":"Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?","volume":"28(2)","author":"Duda","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer","volume":"11(12)","author":"Jubb","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2009.22.4279","article-title":"Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and\/or chemotherapy in patients with non-small-cell lung cancer","volume":"28(2)","author":"Hanrahan","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C8","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan\u2013vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28(17)","author":"Batchelor","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28(11)","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0002-9440(10)62555-2","article-title":"Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo","volume":"160(4)","author":"Ouafik","year":"2002","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C11","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26(22)","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/neuonc\/noq151","article-title":"Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab","volume":"13(1)","author":"Prados","year":"2011","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","article-title":"Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan","volume":"26(2)","author":"Sathornsumetee","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C14","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1002\/cncr.25462","article-title":"A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas","volume":"116(22)","author":"Raizer","year":"2010","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170508185152_NOT226C15","doi-asserted-by":"crossref","first-page":"e19873","DOI":"10.1371\/journal.pone.0019873","article-title":"Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker","volume":"6(5)","author":"Niers","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170508185152_NOT226C16","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27(31)","author":"Roy","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C17","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-07-1253","article-title":"Urinary biomarkers predict brain tumor presence and response to therapy","volume":"14(8)","author":"Smith","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508185152_NOT226C18","first-page":"2009","article-title":"Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer","volume":"20(3B)","author":"Papathoma","year":"2000","journal-title":"Anticancer Res"},{"key":"key\n\t\t\t\t20170508185152_NOT226C19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1006421112839","article-title":"Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms","volume":"46(1)","author":"Jaalinoja","year":"2000","journal-title":"J Neurooncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00401-009-0592-2","article-title":"High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas","volume":"118(6)","author":"Colin","year":"2009","journal-title":"Acta Neuropathol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10014-011-0021-9","article-title":"Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas","volume":"28(2)","author":"Brell","year":"2011","journal-title":"Brain Tumor Pathol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12(3)","author":"de Groot","year":"2010","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10014-010-0271-y","article-title":"Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity","volume":"27(2)","author":"Takano","year":"2010","journal-title":"Brain Tumor Pathol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C24","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-09-0575","article-title":"Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy","volume":"15(14)","author":"Lucio-Eterovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508185152_NOT226C25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1215\/15228517-2008-001","article-title":"Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM","volume":"10(3)","author":"Du","year":"2008","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/path.2854","article-title":"Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair","volume":"224(2)","author":"Tremblay","year":"2011","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20170508185152_NOT226C27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473(7347)","author":"Carmeliet","year":"2011","journal-title":"Nature"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/16\/3\/392\/16664487\/not226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T17:53:44Z","timestamp":1503510824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/not226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,9]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,12,9]]},"published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/not226","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,9]]}}}